Erythropoietin (Epo), the main erythropoiesis‐stimulating factor widely prescribed to
overcome anemia, is also known nowadays for its cytoprotective action on non …

A major goal of contemporary epilepsy research is the identification of therapies to prevent
the development of recurrent seizures in individuals at risk, including those with brain …

Epilepsy is a chronic brain disease that affects approximately 65 million people worldwide.
However, despite the continuous development of antiepileptic drugs, over 30% patients with …

Introduction Chemotherapy-induced cognitive impairment colloquially referred to as
chemobrain is a poorly understood phenomenon affecting a highly variable proportion of …

The most important activity of erythropoietin (EPO) is the regulation of erythrocyte production
by activation of the erythropoietin receptor (EPO-R), which triggers the activation of anti …

INTRODUCTION Recombinant human erythropoietin is used primarily to treat anemia.
There is evidence of its neuroprotective capacity from preclinical studies in Parkinson's …

Introduction: Since erythropoietin (EPO) and EPO receptor (EPOR) are expressed in the
central nervous system (CNS) beyond hematopoietic system, EPO illustrates a robust …

Neurodegenerative disorders such as Alzheimer's disease (AD) are characterized by the
irreversible neuronal loss and memory impairment, and current treatments are merely …

Erythropoietin (EPO) suppresses epileptic seizures, but the mechanism is unclear. The
search for novel targets in the therapy of epilepsy has focused recently on brain …

Purpose To evaluate the incidence rate and risk factors for status epilepticus (SE) after
stroke (PSSE), including ischaemic stroke (IS), intracerebral hemorrhage (ICH), and …